Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | KDM4B | O94953 | 1/20 | 0.30 |
| ▸ | KDM5C | P41229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29224715 | 0.81 | ACVR1B (0.40) | ALDH1A1KDM4ELMNANPC1HTT | |
| SCHEMBL9466419 | 0.74 | NPC1 (0.33) | MAPK1NPC1 | |
| SCHEMBL6355265 | 0.72 | NOTUM (0.37) | NOTUM | |
| SCHEMBL8688771 | 0.68 | KDM4E (0.35) | ALDH1A1KDM4E | |
| SCHEMBL6053126 | 0.67 | KDM4E (0.37) | ALDH1A1KDM4ELMNAMEN1GAA | |
| SCHEMBL11143408 | 0.67 | KDM4E (0.37) | ALDH1A1KDM4ELMNAMEN1GAA | |
| SCHEMBL17476686 | 0.66 | KDM4E (0.48) | ALDH1A1KDM4ELMNAMEN1GAA | |
| SCHEMBL11153808 | 0.65 | KDM4A (0.38) | ALDH1A1KDM4ELMNAMEN1GAA | |
| SCHEMBL11153631 | 0.65 | ALDH1A1 (0.40) | ALDH1A1KDM4ELMNAMEN1GAA | |
| SCHEMBL308284 | 0.65 | F2RL1 (0.41) | ALDH1A1KDM4ELMNAMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1072430-B1 | Ink jet printing process | EASTMAN KODAK CO (US) | 2005-12-14 | — | — | EP | claimed |
| US-6364476-B1 | IMAGE-RECORDING LAYER INCLUDES A MIXTURE OF AN ANIONIC, ADDITION POLYMER AND A HYDROPHILIC POLYMER; INK INCLUDES WATER, HUMECTANT AND A WATER-SOLUBLE CATIONIC OR BASIC DYE; IMPROVED DYE DENSITY AND FIXABILITY | EASTMAN KODAK COMPANY | 2002-04-02 | — | — | US | claimed |
| EP-1153761-A2 | Ink jet printing process | EASTMAN KODAK COMPANY (US) | 2001-11-14 | — | — | EP | claimed |
| US-6280027-B1 | Ink jet printing process | EASTMAN KODAK COMPANY | 2001-08-28 | — | — | US | claimed |
| US-6280026-B1 | Ink jet printing process | EASTMAN KODAK COMPANY | 2001-08-28 | — | — | US | claimed |
| US-6280028-B1 | Ink jet printing process | EASTMAN KODAK COMPANY | 2001-08-28 | — | — | US | claimed |
| EP-1072430-A2 | Ink jet printing process | EASTMAN KODAK COMPANY (US) | 2001-01-31 | — | — | EP | claimed |
| EP-1072431-A2 | Ink jet printing process | EASTMAN KODAK COMPANY (US) | 2001-01-31 | — | — | EP | claimed |
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2025-10-09 | — | — | US | disclosed |
| CN-115279766-B | Combination therapy comprising A2A/A2B and a PD-1/PD-L1 inhibitor | 因赛特公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250059293-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
| US-20250041310-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | INCYTE CORPORATION | 2025-02-06 | — | — | US | disclosed |
| US-20250034153-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2025-01-30 | — | — | US | disclosed |
| CN-112384515-B | Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors | 因赛特公司 | 2024-12-10 | — | — | CN | disclosed |
| US-5834171-A | DEVELOPERS; STORAGE STABILITY | KONICA CORPORATION (JP) | 1998-11-10 | — | — | US | disclosed |
| EP-0785467-A1 | Solid processing composition for silver halide photographic light sensitive material | KONICA CORPORATION (JP) | 1997-07-23 | — | — | EP | disclosed |
| US-5246914-A | Fungicides and plant growth regulators | BASF AKTIENGESELLSCHAFT (DE) | 1993-09-21 | — | — | US | disclosed |
| EP-0087880-B1 | SILVER HALIDE PHOTOGRAPHIC MATERIAL | KONICA CORPORATION (JP) | 1986-05-14 | — | — | EP | disclosed |
| US-4477561-A | PLATIUM, DALLADIUM, RHODIUM, IRIDIUM AND OSMIUM SALTS; LIGHT SENSITIVE | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1984-10-16 | — | — | US | disclosed |
| EP-0087880-A2 | Silver halide photographic material | KONICA CORPORATION (JP) | 1983-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059293-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | ADORA2A, ADORA2B, NT5E | ALDH1A1 565/4885KDM4E 3788/4885LMNA 2681/4885 |
| US-20250041310-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | ADORA2A, ADORA2B, ADORA1 | ALDH1A1 187/4885KDM4E 3443/4885LMNA 2429/4885 |
| US-20250034153-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | ALDH1A1 498/4885KDM4E 4413/4885LMNA 3689/4885 |
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | ALDH1A1 347/4885KDM4E 4274/4885LMNA 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.